Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Herceptin
 More »

  • Companion Diagnostics: 52 Pick-Up
    ... Assesses patients for whom herceptin (trastuzumab) treatment is being considered. Pathway ... Assists in assessment of breast cancer patients for whom Herceptin treatment is being ...
    5-9-2013
  • Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
    ... Zhejiang Huahai will also commercialize Humira, Rituxan, Avastin, and Herceptin for EU, Japan, Canada, and Australia. Oncobiologics Finds Partner to Launch Biosimilars in U.S., ...
    5-8-2013
  • Biosimilars: 10 Drugs to Watch
    ... will seek a partner to commercialize HD203 and a biosimilar for Herceptin (trastuzumab). ... expired 2008 and April 16, 2013 in U.S. Herceptin (trastuzumab) Drug developers: Amgen, ...
    4-22-2013
  • Biosimilars: Not So Far So Fast
    As the industry awaits a range of biologics U.S. patents to expire including Amgen's Neupogen in 2013, Biogen Idec's Avonex in 2013, and Genentech's Herceptin in 2014, remaining ...
    3-15-2013
  • Top 20 Best-Selling Drugs of 2012
    ... CER Q4 2012 sales: $1.622 billion, down 7% at CER from $1.771 billion in Q4 2011 #7. Herceptin (trastuzumab) Drug maker: Roche Indication(s): HER2-positive breast cancer and ...
    3-1-2013
  • Roche's Genentech Wins FDA OK for Breast Cancer Drug
    The newly-approved drug is a combination of Herceptin and DM1, which Kadcyla delivers to the cancer site, shrinking the size of the tumor, slowing disease progression, and ...
    2-22-2013
  • A "Very Good Year" for Roche
    HER2-positive breast cancer, used in combination with Roche's Herceptin and chemotherapy. ... billion ($7.3 billion), while sales of Herceptin for HER2-positive breast and stomach ...
    1-30-2013
  • 15 Breast Cancer Drugs in the Pipeline Right Now
    ... treated with antiestrogen medications Herceptin (Trastuzumab; RG597) Sponsor: Roche, in ... Indications/Phase of Trial: EU: With Herceptin and docetaxel chemotherapy for ...
    11-26-2012
  • Bring a Friend: Cancer Companion Diagnostics Become Popular
    The first diagnostic/treatment pair, Herceptin and HercepTest, was approved in 1998. Since ... responds to antibody therapies (including Herceptin, which targets Her2-positive cancers). ...
    9-5-2012
  • Biotech From the Outside Looking In
    ... What the consumer sees, though, is very different. The miraculous new treatments like Herceptin and Cerezyme to sequencing that can determine drug response and disease ...
    9-5-2012
  • Biomarkers Update-Personalized Medicine
    ... With current biotechnology drugs in the cancer area two markers have shown promise: the HER2 test used with Herceptin therapy and the Kras test used with Erbitux. These genetic ...
    8-10-2012
  • Monoclonal Antibodies Enter Golden Age
    ... Similarly T-DM1 (Roche) combines the breast tumor-seeking antibody Herceptin with Immunogen's TAP cytotoxic agent. Adcertis is approved, T-DM1 is in Phase III, and other related ...
    8-1-2012
  • Breast Cancer News: Preventing Herceptin Resistance
    an IL-6 inhibitor with Herceptin (Roche's humanized antibody therapy trastuzumab). Nearly half of Her2-positive breast cancers are resistant to Herceptin, and those that are ...
    7-20-2012
  • FDA Clears Roche's Perjeta as Combination Therapy for Metastatic...
    for use as combination therapy with Herceptin (trastuzumab) and docetaxel in the ... for patients treated using Perjeta plus Herceptin and docetaxel chemotherapy, compared ...
    6-11-2012
  • Genentech Plans 2012 U.S./EU Filing for T-DM1 in Metastatic Her2...
    Th3resa is comparing trastuzumab emtansine with physician's choice of therapy in people with Her2-positive mBC who have previously received both Herceptin and lapatinib. ...
    6-4-2012

  • Journal Articles

  • 111 In-Labeled Immunoconjugates (ICs) Bispecific for the Epidermal...
    Raymond M. Reilly, Bart Cornelissen, Veerle Kersemans, Kristin McLarty, Lara Tran
    Cancer Biotherapy and Radiopharmaceuticals
    Internalization and nuclear importation were evaluated. Retention of the ICs in H2N or trastuzumab (Herceptin)-resistant HR2 cells exposed to trastuzumab to modulate p27Kip1 ...
  • α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease...
    Diane E. Milenic, Kayhan Garmestani, Erik D. Brady, Paul S. Albert, Dangshe Ma, Alia Abdulla, Martin W. Brechbiel
    Cancer Biotherapy and Radiopharmaceuticals
    peritoneal disease using 212Pb-labeled Herceptin as an in vivo generator of 212Bi. ... The efficacy of 212Pb-Herceptin was also assessed in a human pancreatic carcinoma ...
  • Neoadjuvant Immunotherapy Enhances Radiosensitivity Through Natural...
    Chau-Hwa Chi, Yu-Shan Wang, Chieh-Han Yang, Kwan-Hwa Chi
    Cancer Biotherapy and Radiopharmaceuticals
    Inc., South San Francisco, CA) (CpG/Herceptin), given before or after radiation, was ... coculture of CT26HER2/neu with splenocytes, CpG, and Herceptin before applying radiation. ...
  • In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with...
    Ann-Charlott Steffen, Maria Wikman, Vladimir Tolmachev, Gregory P. Adams, Fredrik Y. Nilsson, Stefan Ståhl, Jörgen Carlsson
    Cancer Biotherapy and Radiopharmaceuticals
    With approximately the same affinity as the monoclonal antibody trastuzumab (Herceptin(tm)) but only one tenth of the size, this new bivalent molecule is a promising candidate for ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll